VolitionRX Ltd (VNRX): Next-Year EPS Estimate 49.13%
As of 2026-07-17, VolitionRX Ltd (VNRX) has a next-year EPS growth estimate of 49.13%. Featured in our EPS revision report on 2026-05-25.
On 2026-07-12, analyst consensus for VNRX's next-year EPS growth shifted from 48.99% to 49.13% — a positive change of 0.14 percentage points. The revised estimate has been sustained across 6 subsequent trading sessions. Current-year growth is projected at 49.18%.
What's Driving This
VolitionRX’s stock rise is primarily driven by a sharp EPS estimate upgrade: on June 21, 2026, analysts raised next-year EPS growth from 40.49% to 48.99% (an 8.50 percentage-point move). This revision is plausibly tied to the Q1 2026 earnings call highlighting a revenue surge, as well as the announcement of a breakthrough finger-prick detection for nucleosomes expanding sepsis testing market potential. Since the initial revision, the estimate has edged up further to 49.13%, indicating continued positive momentum.
Generated 2026-07-17 from news as of 2026-07-17
Current Snapshot
- Sector
- Healthcare
- Industry
- Medical Devices
- EPS growth next year
- 49.13%
- EPS growth this year
- 49.18%
- EPS next quarter (est)
- -$0.61
- Last price
- $1.10
EPS Revision History
| Date | EPS Next Y | EPS This Y | Next Q (est) | Price |
|---|---|---|---|---|
| 2026-07-17 | 49.13% | 49.18% | -$0.61 | $1.10 |
| 2026-07-16 | 49.13% | 49.18% | -$0.61 | $1.16 |
| 2026-07-15 | 49.13% | 49.18% | -$0.61 | $1.18 |
| 2026-07-14 | 49.13% | 49.18% | -$0.61 | $1.27 |
| 2026-07-13 | 49.13% | 49.18% | -$0.61 | $1.30 |
| 2026-07-12 | 49.13% | 49.18% | -$0.61 | $1.35 |
| 2026-07-09 | 48.99% | 49.32% | -$0.60 | $1.34 |
| 2026-07-08 | 48.99% | 49.32% | -$0.60 | $1.35 |
| 2026-07-07 | 48.99% | 49.32% | -$0.60 | $1.40 |
| 2026-07-06 | 48.99% | 49.32% | -$0.60 | $1.35 |
| 2026-07-05 | 48.99% | 49.32% | -$0.60 | $1.40 |
| 2026-07-02 | 48.99% | 49.32% | -$0.60 | $1.40 |
| 2026-07-01 | 48.99% | 49.32% | -$0.60 | $1.36 |
| 2026-06-30 | 48.99% | 49.32% | -$0.60 | $1.35 |
| 2026-06-29 | 48.99% | 49.32% | -$0.60 | $1.42 |
| 2026-06-28 | 48.99% | 49.32% | -$0.60 | $1.28 |
| 2026-06-25 | 48.99% | 49.32% | -$0.60 | $1.29 |
| 2026-06-24 | 48.99% | 49.32% | -$0.60 | $1.23 |
| 2026-06-23 | 48.99% | 49.32% | -$0.60 | $1.21 |
| 2026-06-22 | 48.99% | 49.32% | -$0.60 | $1.34 |
| 2026-06-21 | 48.99% | 49.32% | -$0.60 | $1.43 |
| 2026-06-18 | 40.49% | 47.05% | -$0.62 | $1.43 |
| 2026-06-17 | 40.49% | 47.05% | -$0.62 | $1.37 |
| 2026-06-16 | 40.49% | 47.05% | -$0.62 | $1.40 |
| 2026-06-15 | 40.49% | 47.05% | -$0.62 | $1.44 |
| 2026-06-14 | 40.49% | 47.05% | -$0.62 | $1.38 |
| 2026-06-11 | 40.49% | 47.05% | -$0.62 | $1.46 |
| 2026-06-10 | 40.49% | 47.05% | -$0.62 | $1.39 |
| 2026-06-09 | 40.49% | 47.05% | -$0.62 | $1.36 |
| 2026-06-08 | 40.49% | 47.05% | -$0.62 | $1.39 |
Reports Featuring VNRX
Recent News
- VolitionRX Ltd (VNRX) Q1 2026 Earnings Call Highlights: Revenue Surge and Strategic ...GuruFocus.com
- VolitionRX Ltd (VNRX) Q1 2026 Earnings Call Highlights: Revenue Surge and Strategic ...GuruFocus.com
- Volition Announces Breakthrough Finger-Prick Detection of Nucleosomes; Expanding Global Market Potential for Sepsis TestingPR Newswire
- VolitionRX: Q4 Earnings SnapshotAssociated Press
- VolitionRx Limited Announces Full Fiscal Year 2025 Financial Results and Business UpdatePR Newswire
- VolitionRx Limited Announces Full Fiscal Year 2025 Financial Results and Business UpdatePR Newswire
- VolitionRX Ltd (VNRX) Q4 2025: Everything You Need to Know Ahead of EarningsGuruFocus.com
- VolitionRX Ltd (VNRX) Q4 2025: Everything You Need to Know Ahead of EarningsGuruFocus.com
- VolitionRx Secures EUR 2.0 Million of Non-Dilutive Funding from Regional Government Agencies in BelgiumPR Newswire
- VolitionRx Secures EUR 2.0 Million of Non-Dilutive Funding from Regional Government Agencies in BelgiumPR Newswire
Screen Performance
Aggregate stats across all 1864 tickers our top-EPS-revision screen has flagged over the past 107 days.
- Median return since detection
- +2.5%
- % of tickers in the green
- 55%
- Median return on winners
- +20.8%
- Large revisions captured
- 1048
Past detection performance reflects the price change between when a ticker first entered our screen and the most recent observation. Not a forward-looking forecast.
Also Tracked by Our Screen
Frequently Asked Questions
What is VolitionRX Ltd's next-year EPS growth estimate?▾
As of 2026-07-17, VolitionRX Ltd (VNRX) has a next-year EPS growth estimate of 49.13%, based on analyst consensus.
When was the latest EPS estimate revision for VNRX?▾
The most recent revision occurred on 2026-07-12, when analysts adjusted the next-year EPS growth estimate from 48.99% to 49.13%.
What sector and industry does VolitionRX Ltd belong to?▾
VolitionRX Ltd operates in the Healthcare sector, specifically the Medical Devices industry.
How often is this EPS estimate data updated?▾
EPS revision data is refreshed daily from analyst consensus estimates. VNRX appears on this page because it was flagged by our daily top-EPS-revision-performer screen.
EPS revision data sourced from analyst consensus estimates, refreshed daily. VolitionRX Ltd (VNRX) appears here because it was detected by our daily top-EPS-revision-performer screen.